½ÃÀ庸°í¼­
»óǰÄÚµå
1396585

ÀÓ»ó µ¥ÀÌÅÍ °ü¸® ½Ã½ºÅÛ(CDMS) ½ÃÀå - µô¸®¹ö¸® ¸ðµåº°, ÃÖÁ¾ ¿ëµµº°, ¼¼°è ¿¹Ãø(2023-2032³â)

Clinical Data Management Systems (CDMS) Market - By Delivery Mode (Licensed Enterprise Solutions, Cloud-based Solutions), By End-use (Contract Research Organizations, Medical Device Companies), Global Forecast (2023 - 2032)

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 115 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÀÓ»ó µ¥ÀÌÅÍ °ü¸® ½Ã½ºÅÛ(CDMS) ½ÃÀå ±Ô¸ð´Â ÇコÄÉ¾î µ¥ÀÌÅÍÀÇ µðÁöÅÐÈ­°¡ ÁøÇàµÇ¾î µ¥ÀÌÅÍ º¸¾È ¹× ÄÄÇöóÀ̾𽺰¡ Á߽õʿ¡ µû¶ó 2023³âºÎÅÍ 2032³â¿¡ °ÉÃÄ 11.2%ÀÇ CAGRÀ» ±â·ÏÇÒ Àü¸ÁÀÔ´Ï´Ù.

¹Ì±¹ ÀÇ»çȸ(AMA)ÀÇ µðÁöÅÐ ÇコÄɾî 2022³â Á¶»ç °á°ú¿¡ µû¸£¸é ȯÀÚ Äɾ À§ÇØ µðÁöÅÐ Çï½ºÅøÀ» ¼±ÅÃÇÏ´Â ÀÇ»çÀÇ ¼ö´Â 2016³â 85%¿¡¼­ 2022³â 93%·Î Áõ°¡Çß½À´Ï´Ù.

CDMS ¼Ö·ç¼ÇÀº µ¥ÀÌÅÍ ¾Ïȣȭ»Ó¸¸ ¾Æ´Ï¶ó ¾×¼¼½º Á¦¾î ¹× µ¥ÀÌÅÍ º¸È£ ±ÔÁ¤ Áؼö¸¦ ¿ì¼±½ÃÇÏ´Â µ¥ µµ¿òÀÌ µÇ¹Ç·Î Å« ¼ö¿ä¸¦ ¸¶ÁÖÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ¹× »ý¸í °úÇÐ ºÐ¾ß¿¡¼­ ÀÌ·¯ÇÑ ¼Ö·ç¼ÇÀº µ¥ÀÌÅÍ À¯Ãâ ¹× »çÀ̹ö °ø°Ý°ú °ü·ÃµÈ À§ÇèÀ» ÁÙÀÌ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. °¨»ç ÃßÀû ¹× ¸ð´ÏÅ͸µ ±â´É°ú °°Àº °­·ÂÇÑ º¸¾È ±â´É°úÀÇ ÅëÇÕÀÌ ÁøÇàµÊ¿¡ µû¶ó ½ÃÀå ¼ºÀåÀ» °áÁ¤ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Á¦°ø Çüź°·Î´Â ¶óÀ̼±½ºÇü ¿£ÅÍÇÁ¶óÀÌÁî(¿ÂÇÁ·¹¹Ì½º) ¼Ö·ç¼Ç ½ÃÀå Á¡À¯À²ÀÌ 2023³âºÎÅÍ 2032³â¿¡ °ÉÃÄ CAGR 10% ÀÌ»óÀ¸·Î È®´ëµÉ Àü¸ÁÀÔ´Ï´Ù. ÀÌ´Â ¿ÂÇÁ·¹¹Ì½º CDMS ¼Ö·ç¼ÇÀÌ Á¶Á÷¿¡ µ¥ÀÌÅÍ º¸¾È ¹× ±ÔÁ¤ Áؼö Ãø¸é¿¡¼­ ´õ Å« ÄÁÆ®·ÑÀ» Á¦°øÇϱ⠶§¹®¿¡ ¼±È£µµ°¡ ³ô¾ÆÁö°í Àֱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ¼Ö·ç¼ÇÀº ¼ÒÇÁÆ®¿þ¾î ȯ°æ Àü¹Ý¿¡ °ÉÃÄ °í±Þ »ç¿ëÀÚ Á¤ÀÇ ¹× Á¦¾î¸¦ Á¦°øÇÕ´Ï´Ù. ´ë±Ô¸ð µ¥ÀÌÅÍ ¼¼Æ®¿Í ƯÁ¤ ¼º´É ¿ä±¸ »çÇ×À» °¡Áø Á¶Á÷µµ ÃÖÀûÈ­µÈ ¼º´ÉÀ» º¸ÀåÇϱâ À§ÇØ ¿ÂÇÁ·¹¹Ì½º CDMS ±â¼úÀ» ¼±ÅÃÇÕ´Ï´Ù.

ÃÖÁ¾ ¿ëµµ¿¡ ±Ù°ÅÇÏ¿©, ÀÓ»ó½ÃÇè µ¥ÀÌÅÍÀÇ ¼öÁý, ºÐ¼®, º¸°í µî º¹ÀâÇÑ ÇÁ·Î¼¼½º¸¦ ÇÕ¸®È­ÇÏ°í °ü¸®ÇÏ´Â ¿ä±¸°¡ ³ô¾ÆÁü¿¡ µû¶ó ÀÇ·á±â±â ±â¾÷ ºÎ¹®ÀÇ ÀÓ»ó µ¥ÀÌÅÍ °ü¸® ½Ã½ºÅÛ »ê¾÷ °¡Ä¡´Â 2023³âºÎÅÍ 2032³â±îÁö 9.6%ÀÇ ¼ºÀå·üÀ» ±â·ÏÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. CDMS´Â ÀüÀÚ µ¥ÀÌÅÍ ¼öÁý(EDC) ±â´ÉÀ» ÅëÇØ µ¥ÀÌÅÍ ¼öÁý ÇÁ·Î¼¼½ºÀÇ ´Ü¼øÈ­¸¦ Áö¿øÇÕ´Ï´Ù. ½Ç½Ã°£ µ¥ÀÌÅÍ ÀÔ·Â, Á¾ÀÌ ±â¹Ý ¹æ¹ý¿¡ ´ëÇÑ ÀÇÁ¸µµ °¨¼Ò, µ¥ÀÌÅÍ Àü±â ½Ç¼ö À§Çè ÃÖ¼ÒÈ­ µîÀÇ ÀÌÁ¡µµ ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÕ´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ CDMS ½ÃÀå ±Ô¸ð´Â 2032³â±îÁö 13.2%ÀÇ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ´Â ¸ð¹ÙÀÏ ¹× ¿þ¾î·¯ºí ±â¼úÀÇ ÅëÇÕÀÌ ÁøÇàµÇ¾î ȯÀÚ Áß½ÉÀÇ ÀÓ»ó½ÃÇèÀ» À§ÇÑ ½Ç½Ã°£ µ¥ÀÌÅÍ È¹µæ, ȯÀÚ Âü¿©, ¸ð´ÏÅ͸µÀÌ È®½ÇÈ÷ ÀÌ·ç¾îÁö±â ¶§¹®ÀÔ´Ï´Ù. ÇコÄÉ¾î µ¥ÀÌÅÍÀÇ µðÁöÅÐÈ­°¡ ÁøÇàµÊ¿¡ µû¶ó µ¥ÀÌÅÍ º¸¾È ¹× ±ÔÁ¦ ¿ä±¸ »çÇ׿¡ ´ëÇÑ ÄÄÇöóÀ̾𽺰¡ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. µ¥ÀÌÅÍ °ü¸® ±â¼úÀÇ Ç¥ÁØÈ­¸¦ À§ÇÑ ³ë·Â Áõ°¡´Â ÀÌ Áö¿ªÀÇ »ê¾÷ È®´ë¸¦ µÞ¹ÞħÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý ¹× Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ÀÓ»ó µ¥ÀÌÅÍ °ü¸® ½Ã½ºÅÛ(CDMS) ¾÷°è ÀλçÀÌÆ®

  • »ýÅÂ°è ºÐ¼®
  • ¾÷°è Á¤¼¼(2018-2032³â)
  • ¾÷°è¿¡ ¹ÌÄ¡´Â ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ÀÓ»ó µ¥ÀÌÅÍ °ü¸® ½Ã½ºÅÛ(CDMS)ÀÇ Ã¤¿ë Áõ°¡
      • ÀÓ»ó½ÃÇè ¼ö Áõ°¡
      • ±â¼úÀÇ Áøº¸
    • ¾÷°èÀÇ ÀáÀçÀû À§Çè ¹× °úÁ¦
      • ÇÁ¶óÀ̹ö½Ã ¹× µ¥ÀÌÅÍ¿¡ ´ëÇÑ ¿ì·Á
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • COVID-19ÀÇ ¿µÇ⠺м®
  • ±ÔÁ¦ »óȲ
    • ¹Ì±¹
    • À¯·´
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­¹®
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ÀÓ»ó µ¥ÀÌÅÍ °ü¸® ½Ã½ºÅÛ(CDMS) ½ÃÀå : µô¸®¹ö¸® ¸ðµåº°(2018-2032³â)

  • ÁÖ¿ä µ¿Çâ : µô¸®¹ö¸® ¸ðµåº°
  • ¶óÀ̼±½ÌÇü(¿ÂÇÁ·¹¹Ì½º) ¼Ö·ç¼Ç
  • Ŭ¶ó¿ìµå ±â¹Ý(SaaS) ¼Ö·ç¼Ç
  • À¥ È£½ºÆÃ(¿Âµð¸Çµå) ¼Ö·ç¼Ç

Á¦6Àå ÀÓ»ó µ¥ÀÌÅÍ °ü¸® ½Ã½ºÅÛ(CDMS) ½ÃÀå : ÃÖÁ¾ ¿ëµµº°(2018-2032³â)

  • ÁÖ¿ä µ¿Çâ : ÃÖÁ¾ ¿ëµµº°
  • CRO(ÀǾàǰ °³¹ß ¾÷¹« ¼öŹ ±â°ü)
  • ÀÇ·á±â±â ±â¾÷
  • Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • ±âŸ ÃÖÁ¾ »ç¿ëÀÚ

Á¦7Àå ÀÓ»ó µ¥ÀÌÅÍ °ü¸® ½Ã½ºÅÛ(CDMS) ½ÃÀå : Áö¿ªº°(2018-2032³â)

  • ÁÖ¿ä µ¿Çâ : Áö¿ªº°
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ±âŸ MEA

Á¦8Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • eClinical Solutions LLC
  • CIMS Global
  • Axiom Real-Time Metrics
  • IBM Watson Health
  • Veeva System
  • Oracle Corporation
  • Ennov
  • Medidata Solutions(Dassault Systems)
  • Fortress Medical
  • OpenClinica, LLC
AJY 23.12.21

Clinical Data Management Systems (CDMS) Market size is poised to record 11.2% CAGR from 2023-2032, on account of the increasing digitization of healthcare data and the heightened emphasis on data security and compliance. As per the American Medical Association (AMA) digital health care 2022 study findings, the number of physicians opting for digital health tools for patient care grew from 85% in 2016 to 93% in 2022.

CDMS solutions are witnessing significant demand as they help to prioritize data encryption as well as access controls and compliance with data protection regulations. In healthcare and life sciences sectors, these solutions help mitigate the risks associated with data breaches and cyberattacks. Increasing integration with robust security features, including audit trails and monitoring capabilities will also define the market growth.

The overall CDMS industry is segmented into delivery mode, end-use, and region.

In terms of delivery mode, the market share from the licensed enterprise (on-premise) solutions segment will expand at over 10% CAGR from 2023-2032. This can be attributed to the growing preference for on-premise CDMS solutions as they offer greater control to organizations over data security and compliance. These solutions also provide high level of customization and control throughout the software environment. Organizations with large datasets and specific performance requirements also opt for on-premise CDMS technology to ensure optimized performance.

Based on end-use, the clinical data management systems industry value from the medical device companies segment may witness 9.6% growth rate from 2023-2032 driven by the surging need to streamline and manage complex processes of collecting, analyzing, and reporting clinical trial data. CDMS helps simplify the process of data collection on account of its electronic data capture (EDC) capabilities. Advantages, such as real-time data entry, reduced reliance on paper-based methods and minimized risk of data transcription errors will also boost the segment growth.

Regionally, the Asia Pacific CDMS market size is projected to record 13.2% CAGR through 2032 owing to the rising integration of mobile and wearable technologies to ensure real-time data capture, engagement patient and monitoring for more patient-centric clinical trials. With increasing digitization of healthcare data, the emphasis on data security and compliance with regulatory requirements has significantly heightened. The increasing efforts led towards standardization of data management practices will push the regional industry expansion.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market definition & scope
  • 1.2 Base estimates & calculations
  • 1.3 Forecast parameters
  • 1.4 COVID-19 impact analysis at global level
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Global clinical data management system (CDMS) industry 360 degree synopsis, 2018 - 2032
    • 2.1.1 Business trends
    • 2.1.2 Regional trends
    • 2.1.3 Delivery mode trends
    • 2.1.4 End-use trends

Chapter 3 Clinical Data Management Systems (CDMS) Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry landscape, 2018 - 2032 (USD Million)
  • 3.3 Industry impact forces
    • 3.3.1 Growth drivers
      • 3.3.1.1 Increasing adoption of clinical data management systems (CDMS)
      • 3.3.1.2 Growing number of clinical trials
      • 3.3.1.3 Growing technological advancements
    • 3.3.2 Industry pitfalls & challenges
      • 3.3.2.1 Privacy and data concerns
  • 3.4 Growth potential analysis
    • 3.4.1 By delivery mode
    • 3.4.2 By end-use
  • 3.5 COVID-19 impact analysis
  • 3.6 Regulatory landscape
    • 3.6.1 U.S.
    • 3.6.2 Europe
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

  • 4.1 Introduction
  • 4.2 Company matrix analysis, 2022
  • 4.3 Competitive analysis of major market players, 2022
  • 4.4 Competitive positioning matrix, 2022
  • 4.5 Strategic dashboard, 2022

Chapter 5 Clinical Data Management Systems (CDMS) Market, By Delivery Mode, 2018 - 2032 (USD Million)

  • 5.1 Key trends, by delivery mode
  • 5.2 Licensed enterprise (on-premise) solutions
  • 5.3 Cloud-based (SaaS) solutions
  • 5.4 Web-hosted (on-demand) solutions

Chapter 6 Clinical Data Management Systems (CDMS) Market, By End-use, 2018 - 2032 (USD Million)

  • 6.1 Key trends, by end-use
  • 6.2 Contract research organization (CROs)
  • 6.3 Medical device companies
  • 6.4 Pharma/biotech companies
  • 6.5 Other end-users

Chapter 7 Clinical Data Management Systems (CDMS) Market, By Region, 2018 - 2032 (USD Million)

  • 7.1 Key trends, by region
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 France
    • 7.3.4 Spain
    • 7.3.5 Italy
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 Rest of Asia Pacific
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Mexico
    • 7.5.3 Rest of Latin America
  • 7.6 MEA
    • 7.6.1 South Africa
    • 7.6.2 Saudi Arabia
    • 7.6.3 Rest of MEA

Chapter 8 Company Profiles

  • 8.1 eClinical Solutions LLC
  • 8.2 CIMS Global
  • 8.3 Axiom Real-Time Metrics
  • 8.4 IBM Watson Health
  • 8.5 Veeva System
  • 8.6 Oracle Corporation
  • 8.7 Ennov
  • 8.8 Medidata Solutions (Dassault Systems)
  • 8.9 Fortress Medical
  • 8.10 OpenClinica, LLC
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦